Molecular Oncology

Print ISSN
1574-7891
Electronic ISSN
1878-0261
Impact factor
4.25
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/15747891
Usage rank
8492
Article count
249
Free count
50
Free percentage
0.200803
PDFs via platforms
Sciencedirect, Proquest, CSA, and Gale

  1. Editorial Board
    Author(s) unavailable

    Molecular Oncology 9(9):ii (2015)

  2. Editorial Board
    Author(s) unavailable

    Molecular Oncology 9(5):ii (2015)

  3. Editorial Board
    Author(s) unavailable

    Molecular Oncology 9(4):ii (2015)

  4. Editorial Board
    Author(s) unavailable

    Molecular Oncology 9(3):ii (2015)

  5. Editorial Board
    Author(s) unavailable

    Molecular Oncology 9(2):ii (2015)

  6. Corrigendum to “Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III” [Mol. Oncol. 8 (2) (2014) 417–30]

    Molecular Oncology 9(1) (2015)

  7. Editorial Board
    Author(s) unavailable

    Molecular Oncology 9(1):ii (2015)

  8. Editorial Board
    Author(s) unavailable

    Molecular Oncology 8(8):ii (2014)

  9. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells

    Molecular Oncology 8(7):1181 (2014) PMID 24768038

    Sphingosine 1-phosphate (S1P) plays important roles in cell proliferation, differentiation or survival mainly through its surface G-protein-coupled receptors S1P1−5. Bone represents the major site of metastasis for prostate cancer (CaP) cells, which rely on bone-derived factors to supp...
  10. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer

    Molecular Oncology 8(7):1169 (2014) PMID 25266362 PMCID PMC4183720

    Fusions between the transmembrane protease serine 2 (TMPRSS2) and ETS related gene (ERG) represent one of the most specific biomarkers that define a distinct molecular subtype of prostate cancer. Studies of TMPRSS2-ERG gene fusions have seldom been performed at the protein level, prima...
  11. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth

    Molecular Oncology 8(7):1220 (2014) PMID 24816188 PMCID PMC4198498

    Little is known regarding molecular markers in head and neck squamous cell carcinoma (HNSCC) that predict responsiveness to different therapeutic regimens or predict HNSCC progression. Mutations in procaspase-8 occur in 9% of HNSCC primary tumors, but the functional consequences of the...
  12. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis

    Molecular Oncology 8(7):1355 (2014) PMID 24910389 PMCID PMC4198473

    SLUG represses E-cadherin to promote epithelial–mesenchymal transition (EMT) in various cancers. Mechanisms that regulate SLUG/E-cadherin pathway remain poorly understood, especially during tumorigenesis in vivo. Here we report that p19Arf (p14ARF in human) stabilizes Slug to inhibit E...
  13. Molecular pathology – The value of an integrative approach

    Molecular Oncology 8(7):1163 (2014) PMID 25160635

    Molecular Pathology (MP) is at the heart of modern diagnostics and translational research, but the controversy on how MP is best developed has not abated. The lack of a proper model or trained pathologists to support the diagnostic and research missions makes MP a rare commodity overal...
  14. Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information

    Molecular Oncology 8(7):1290 (2014) PMID 24839936

    Little is known about the difference in gene expression between carcinoma-associated fibroblasts (CAFs) and paired normal colonic fibroblasts (NCFs) in colorectal cancer. Paired CAFs and NCFs were isolated from eight primary human colorectal carcinoma specimens. In culture conditions, ...
  15. Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts

    Molecular Oncology 8(7):1253 (2014) PMID 24837184 PMCID PMC4198499

    The aggressiveness of pancreatic cancer is associated with the acquisition of mesenchymal characteristics by a subset of pancreatic cancer cells. The factors driving the development of this subset are not well understood. In this study, we tested the hypothesis that acquisition of a me...
  16. Transcriptional coexpression network reveals the involvement of varying stem cell features with different dysregulations in different gastric cancer subtypes

    Molecular Oncology 8(7):1306 (2014) PMID 24917244

    Despite the advancements in the cancer therapeutics, gastric cancer ranks as the second most common cancers with high global mortality rate. Integrative functional genomic investigation is a powerful approach to understand the major dysregulations and to identify the potential targets ...
  17. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer

    Molecular Oncology 8(7):1339 (2014) PMID 24908424 PMCID PMC4450766

    Better approaches are needed to evaluate a single patient's drug response at the genomic level. Targeted therapy for signaling pathways in cancer has met limited success in part due to the exceedingly interwoven nature of the pathways. In particular, the highly complex RAS network has ...
  18. Editorial Board
    Author(s) unavailable

    Molecular Oncology 8(7):ii (2014)

  19. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing

    Molecular Oncology 8(7):1208 (2014) PMID 24785186 PMCID PMC4198444

    Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. Systematically characterizing miRNAs in NSCLC will help develop biomarkers for its diagnosis and subclassification, and identify therapeutic targets for the treatment. We used next-generation deep sequencing to co...
  20. Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer

    Molecular Oncology 8(7):1278 (2014) PMID 24853384

    The majority of gene expression signatures developed to predict the likelihood to relapse in breast cancer (BC) patients assigns a high risk score to patients with Estrogen Receptor (ER) negative or highly proliferating tumors. We aimed to identify a signature of differentially express...